CFB
CRL icon

Cullen/Frost Bankers’s Charles River Laboratories CRL Stock Holding History

Cullen/Frost Bankers’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15K Sell
66
-45
-41% -$8.01K ﹤0.01% 1107
2026
Q1 		$19.1K Sell
111
-3
-3% -$556 ﹤0.01% 989
2025
Q4 		$22.7K Sell
114
-9
-7% -$1.63K ﹤0.01% 970
2025
Q3 		$19.2K Sell
123
-46
-27% -$7.31K ﹤0.01% 955
2025
Q2 		$25.6K Sell
169
-365
-68% -$48.7K ﹤0.01% 878
2025
Q1 		$80.4K Sell
534
-18,748
-97% -$3.14M ﹤0.01% 642
2024
Q4 		$3.56M Sell
19,282
-2,391
-11% -$461K 0.05% 214
2024
Q3 		$4.27M Sell
21,673
-3,375
-13% -$701K 0.06% 206
2024
Q2 		$5.17M Sell
25,048
-126
-0.5% -$28.6K 0.07% 192
2024
Q1 		$6.82M Buy
25,174
+11
+0% +$2.63K 0.1% 187
2023
Q4 		$5.95M Sell
25,163
-678
-3% -$133K 0.09% 189
2023
Q3 		$5.06M Buy
25,841
+756
+3% +$155K 0.09% 193
2023
Q2 		$5.27M Buy
25,085
+982
+4% +$195K 0.09% 192
2023
Q1 		$4.86M Buy
24,103
+20,671
+602% +$4.68M 0.09% 193
2022
Q4 		$748K Sell
3,432
-894
-21% -$195K 0.01% 330
2022
Q3 		$851K Sell
4,326
-287
-6% -$62K 0.02% 303
2022
Q2 		$987K Buy
4,613
+436
+10% +$107K 0.02% 293
2022
Q1 		$1.19M Buy
4,177
+515
+14% +$159K 0.02% 284
2021
Q4 		$1.38M Sell
3,662
-1,252
-25% -$486K 0.03% 270
2021
Q3 		$2.03M Sell
4,914
-26
-0.5% -$10.8K 0.04% 245
2021
Q2 		$1.83M Buy
4,940
+318
+7% +$106K 0.04% 251
2021
Q1 		$1.34M Sell
4,622
-53
-1% -$14.7K 0.03% 274
2020
Q4 		$1.17M Sell
4,675
-355
-7% -$84.5K 0.03% 271
2020
Q3 		$1.14M Sell
5,030
-83
-2% -$17.2K 0.03% 264
2020
Q2 		$891K Buy
5,113
+4,787
+1,468% +$764K 0.02% 287
2020
Q1 		$41K Buy
326
+103
+46% +$15.4K ﹤0.01% 532
2019
Q4 		$34K Buy
+223
New +$30.9K ﹤0.01% 670

Other funds holding CRL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CB
Cooke & Bieler Philadelphia, Pennsylvania $8.65B AUM 9.66% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
VBA
Van Berkom & Associates Montreal, Quebec, Canada $3.1B AUM 12.88% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return

Cullen/Frost Bankers's CRL Position: Q2 2026 in Review

Cullen/Frost Bankers reduced its Charles River Laboratories (CRL) stake by 41% in Q2 2026, selling an estimated $8.01K and leaving 66 shares worth $15K. The position accounts for ﹤0.01% of the portfolio, ranked #1107.

Cullen/Frost Bankers first reported a position in CRL in Q4 2019 and has held it in 27 quarters since. The position peaked at $6.82M in Q1 2024. 279 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • Cullen/Frost Bankers held 66 shares of Charles River Laboratories worth $15K as of Q2 2026.
  • Cullen/Frost Bankers sold 45 Charles River Laboratories shares in Q2 2026, an estimated $8.01K.
  • Charles River Laboratories made up ﹤0.01% of Cullen/Frost Bankers's portfolio in Q2 2026, its #1107 holding.
  • Cullen/Frost Bankers first reported a position in Charles River Laboratories in Q4 2019 and has held it in 27 quarters since.
  • Cullen/Frost Bankers's Charles River Laboratories position peaked at $6.82M in Q1 2024.
  • 279 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Cullen/Frost Bankers's 13F filing for Q2 2026, filed 27 Jul 2026.